Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Diagnostics of Inflammatory Bowel Disease
share announcement

Diagnostics of Inflammatory Bowel Disease

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 5985

Special Issue Editors

Dr. Hidetoshi Takedatsu

E-Mail
Guest Editor
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan
Interests: inflammatory bowel disease; mucosal immuology; immunology
Prof. Dr. Keiichi Mitsuyama

E-Mail
Guest Editor
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
Interests: inflammatory bowel disease; mucosal immunology

Special Issue Information

Dear colleagues,

The diagnosis of inflammatory bowel disease (IBD) with Crohn’s disease (CD) and ulcerative colitis (UC) is based on clinical, endoscopic, radiologic, and histologic criteria. Although the characteristics of CD and UC differ, accurate diagnosis of IBD is sometimes difficult.

The new technologies have improved the identification of biomarkers and genetic susceptibilities in IBD. They help to avoid endoscopic and imaging examinations and to detect early disease or predict the individual course of disease.

Therefore, establishing the diagnostic algorithms of IBD in biomarkers of serums, feces, tissues, gut microbiota, and genetic susceptibility factors is important.

Dr. Hidetoshi Takedatsu
Prof. Keiichi Mitsuyama
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • biomarker
  • gut microbiota
  • genetic susceptibility

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 260 KiB  
Article
The Association of Plasma-Free Branched-Chain Amino Acids with Disease Related Parameters in Ulcerative Colitis
by Efstathia Papada, Charalampia Amerikanou, Aristea Gioxari, Nick Kalogeropoulos and Andriana C. Kaliora
Diagnostics 2020, 10(10), 798; https://doi.org/10.3390/diagnostics10100798 - 8 Oct 2020
Cited by 4 | Viewed by 2206
Abstract
Branched-chain amino acids (BCAAs) are involved in immune system’s metabolic pathways and play fundamental role in gut health. Our aim was to assess BCAA plasma levels in patients with ulcerative colitis (UC) and associations of plasma BCAAs with disease-related parameters. This was a [...] Read more.
Branched-chain amino acids (BCAAs) are involved in immune system’s metabolic pathways and play fundamental role in gut health. Our aim was to assess BCAA plasma levels in patients with ulcerative colitis (UC) and associations of plasma BCAAs with disease-related parameters. This was a case-control study in adult patients with UC and BMI-matched controls. A total of 150 volunteers were screened between May 2016 and June 2017; 43 patients and 34 healthy controls were enrolled. Medical and dietary history (3 × 24 h recalls, MedDiet score), anthropometric measurements, blood and fecal samples were collected. We measured BCAAs in plasma with gas chromatography-mass spectrometry. In patients, fecal calprotectin, lactoferrin, lysozyme and defensin were quantified. Dietary pattern was similar in patients and controls. Plasma-free BCAA profiles did not differ between groups. Regression analysis showed that i) valine was inversely associated with calprotectin (p = 0.007) and ii) isoleucine with age (p = 0.031), after adjusting for age, sex, PMS and smoking. Leucine was negatively associated with age (p = 0.015) after adjusting for age, sex and PMS, but this association vanished when smoking was introduced. No correlation was observed between total BCAAs with any of the parameters. Plasma-free valine is negatively associated with calprotectin in patients with UC. Full article
(This article belongs to the Special Issue Diagnostics of Inflammatory Bowel Disease)

Review

Jump to: Research

12 pages, 316 KiB  
Review
A Review of Selected IBD Biomarkers: From Animal Models to Bedside
by Emiko Mizoguchi, Renuka Subramaniam, Toshiyuki Okada and Atsushi Mizoguchi
Diagnostics 2021, 11(2), 207; https://doi.org/10.3390/diagnostics11020207 - 30 Jan 2021
Cited by 8 | Viewed by 3287
Abstract
Inflammatory bowel disease (IBD) is a dysregulated inflammatory condition induced by multiple factors. The etiology of IBD is largely unknown, and the disease progression and prognosis are variable and unpredictable with uncontrolled disease behavior. Monitoring the status of chronic colitis closely is challenging [...] Read more.
Inflammatory bowel disease (IBD) is a dysregulated inflammatory condition induced by multiple factors. The etiology of IBD is largely unknown, and the disease progression and prognosis are variable and unpredictable with uncontrolled disease behavior. Monitoring the status of chronic colitis closely is challenging for physicians, because the assessment of disease activity and severity require invasive methods. Using laboratory biomarkers may provide a useful alternative to invasive methods in the diagnosis and management of IBD. Furthermore, patients with ulcerative colitis or Crohn’s disease are also at risk of developing cancer. Annual colonoscopies can help lower the risk for developing colorectal cancer. However, laboratory biomarkers may also be helpful as non-invasive indicators in predicting treatment responses, improving prognosis, and predicting possible tumors. This review addresses selected laboratory biomarkers (including ANCA, chitinase 3-like 1, S100A12/RAGE, calprotectin, and TNF/TNFR2), which are identified by utilizing two well-accepted animal models of colitis, dextran sodium sulfate-induced and T cell receptor alpha knockout colitis models. In addition to being useful for monitoring disease severity, these biomarkers are associated with therapeutic strategies. The factors may regulate the initiation and perpetuation of inflammatory factors in the gut. Full article
(This article belongs to the Special Issue Diagnostics of Inflammatory Bowel Disease)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop